Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017-2022

In 2021, the World Health Organization recommended new extensively drug-resistant (XDR) and pre-XDR tuberculosis (TB) definitions. In a recent cohort of TB patients in Eastern Europe, we show that XDR TB as currently defined is associated with exceptionally poor treatment outcomes, considerably wors...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2024-04, Vol.30 (4), p.831-833
Main Authors: Dahl, Victor Naestholt, Butova, Tetiana, Rosenthal, Alex, Grinev, Alina, Gabrielian, Andrei, Vashakidze, Sergo, Shubladze, Natalia, Toxanbayeva, Bekzat, Chingissova, Lyailya, Crudu, Valeriu, Chesov, Dumitru, Kalmambetova, Gulmira, Saparova, Gulbarchyn, Wejse, Christian Morberg, Butov, Dmytro
Format: Article
Language:English
Subjects:
bacteria
Clinical outcomes
disease management
Drug resistance
Drug resistance in microorganisms
Drug therapy
Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017–2022
Epidemiology
extensively drug-resistant tuberculosis
Georgia (Republic) - epidemiology
Hospitals
Humans
Infectious diseases
Kazakhstan - epidemiology
Kyrgyzstan - epidemiology
Medical colleges
Meta-analysis
Moldova - epidemiology
multidrug-resistant tuberculosis
Patients
R&D
Research & development
Research Letter
Rifampin
Success
treatment outcome
Tuberculosis
tuberculosis and other mycobacteria
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Ukraine - epidemiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2021, the World Health Organization recommended new extensively drug-resistant (XDR) and pre-XDR tuberculosis (TB) definitions. In a recent cohort of TB patients in Eastern Europe, we show that XDR TB as currently defined is associated with exceptionally poor treatment outcomes, considerably worse than for the former definition (31% vs. 54% treatment success).
ISSN:1080-6040
1080-6059
DOI:10.3201/eid3004.231732